Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1.

Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GR 3rd, Song LY, Dankner WM, Oleske JM; Pediatric AIDS Clinical Trials Group Protocol 219 Team.

N Engl J Med. 2001 Nov 22;345(21):1522-8.

2.

Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.

Storm DS, Boland MG, Gortmaker SL, He Y, Skurnick J, Howland L, Oleske JM; Pediatric AIDS Clinical Trials Group Protocol 219 Study Team.

Pediatrics. 2005 Feb;115(2):e173-82. Epub 2005 Jan 3.

PMID:
15629958
3.

Antiretroviral therapy during pregnancy and the risk of an adverse outcome.

Tuomala RE, Shapiro DE, Mofenson LM, Bryson Y, Culnane M, Hughes MD, O'Sullivan MJ, Scott G, Stek AM, Wara D, Bulterys M.

N Engl J Med. 2002 Jun 13;346(24):1863-70.

4.

Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.

Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage GR 3rd; Pediatric AIDS Clinical Trials Group 219/219C Study Team.

Clin Infect Dis. 2008 Feb 15;46(4):507-15. doi: 10.1086/526524.

5.

Osteonecrosis of the hip (Legg-Calvé-Perthes disease) in human immunodeficiency virus-infected children.

Gaughan DM, Mofenson LM, Hughes MD, Seage GR 3rd, Ciupak GL, Oleske JM; Pediatric AIDS Clinical Trials Group Protocol 219 Team.

Pediatrics. 2002 May;109(5):E74-4.

PMID:
11986480
6.

Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children.

Buchacz K, Cervia JS, Lindsey JC, Hughes MD, Seage GR 3rd, Dankner WM, Oleske JM, Moye J.

Pediatrics. 2001 Oct;108(4):E72.

PMID:
11581480
7.

The effect of protease inhibitor therapy on growth and body composition in human immunodeficiency virus type 1-infected children.

Miller TL, Mawn BE, Orav EJ, Wilk D, Weinberg GA, Nicchitta J, Furuta L, Cutroni R, McIntosh K, Burchett SK, Gorbach SL.

Pediatrics. 2001 May;107(5):E77.

PMID:
11331727
8.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
9.

Height, weight, and growth in children born to mothers with HIV-1 infection in Europe.

Newell ML, Borja MC, Peckham C; European Collaborative Study.

Pediatrics. 2003 Jan;111(1):e52-60.

PMID:
12509595
10.

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.

Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr, Deyton LR, Chodakewitz JA, Fischl MA.

N Engl J Med. 1997 Sep 11;337(11):725-33.

11.
12.

Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.

Bedell R, Heath KV, Hogg RS, Wood E, Press N, Yip B, O'Shaughnessy MV, Montaner JS.

Antivir Ther. 2003 Oct;8(5):379-84.

PMID:
14640384
13.

Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.

Englund JA, Baker CJ, Raskino C, McKinney RE, Petrie B, Fowler MG, Pearson D, Gershon A, McSherry GD, Abrams EJ, Schliozberg J, Sullivan JL.

N Engl J Med. 1997 Jun 12;336(24):1704-12.

14.

Mortality in a cohort of HIV-infected adults started on a protease inhibitor-containing therapy: standardization to the general population.

Lewden C, Raffi F, Chêne G, Sobel A, Leport C; APROCO Study Group.

J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):480-2.

PMID:
11391169
15.

Effects of malaria infection in human immunodeficiency virus type 1-infected Ugandan children.

Kalyesubula I, Musoke-Mudido P, Marum L, Bagenda D, Aceng E, Ndugwa C, Olness K.

Pediatr Infect Dis J. 1997 Sep;16(9):876-81.

PMID:
9306483
16.

Protease inhibitor therapy in children with perinatally acquired HIV infection.

Rutstein RM, Feingold A, Meislich D, Word B, Rudy B.

AIDS. 1997 Oct;11(12):F107-11.

PMID:
9342062
17.

Race and sex differences in antiretroviral therapy use and mortality among HIV-infected persons in care.

Lemly DC, Shepherd BE, Hulgan T, Rebeiro P, Stinnette S, Blackwell RB, Bebawy S, Kheshti A, Sterling TR, Raffanti SP.

J Infect Dis. 2009 Apr 1;199(7):991-8. doi: 10.1086/597124.

18.
19.

Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals.

Ramos JT, De José MI, Dueñas J, Fortuny C, González-Montero R, Mellado MJ, Mur A, Navarro M, Otero C, Pocheville I, Muñoz-Fernández MA, Cabrero E; Spanish Collaborative Group on HIV Infection in Children.

Pediatr Infect Dis J. 2005 Oct;24(10):867-73.

PMID:
16220083
20.

Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.

Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S, Sun E; M98-863 Study Team.

N Engl J Med. 2002 Jun 27;346(26):2039-46.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk